Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 36

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 36
---
 forms a part of, have an exercise price of
$2.99 per share, while the closing price of the common stock was $1.35 per share on September 3, 2025. Since both the Inducement Warrants
are currently worth less than what an investor would pay per share, the Selling Securityholders are unlikely to exercise. Cash proceeds
associated with the exercise(s) of the Inducement Warrants, if any, are dependent on the Company’s stock price at the time of exercise.

The Company Offering is a best-efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.

The placement agent has agreed
to use its reasonable best efforts to solicit offers to purchase the securities in the Company Offering. The placement agent has no obligation
to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities.
There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no
minimum offering amount required as a condition to the closing of the Company Offering, the actual offering amount, placement agent fees
and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth herein. We may sell
fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors
in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued
operations, including our near-term continued operations. Thus, we may not raise the amount of capital we believe is required for our
operations in the short-term and may need to raise additional funds to complete such short-term operations. Such additional fundraises
may not be available or available on terms acceptable to us.

| 22 |

If you purchase our securities in either the Company Offering or the Inducement Offering you may incur immediate and substantial dilution in the book value of your shares.

The combined public offering
price per share of our common stock and accompanying warrant may be substantially higher than the net tangible book value per share of
our common stock immediately prior to the offering. After giving effect to the assumed sale of shares of our common stock and accompanying
warrants in this Company Offering, at a combined public offering price of $ 0.90 per share and